Abstracts tagged "ANCA"

Abstract Number: 2078 • 2016 ACR/ARHP Annual Meeting
Global Ethnic and Geographic Differences in the Clinical Features of ANCA-Associated Vasculitis
Fiona Pearce¹, Anthea Craven², Peter A. Merkel³, Raashid Luqmani⁴ and Richard A. Watts⁵, ¹Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁵Rheumatology Department, Ipswich Hospital, Ipswich, Great Britain
Background/Purpose: There are few data on clinical profiles of ANCA-associated vasculitis (AAV) and or ANCA specificity in different ethnic populations. This study examined differences in…
Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson², Rodrigo Cartin-Ceba³, James A. Garrity⁴, Wendy M. Smith⁵, Ulrich Specks⁶, Eric L. Matteson¹ and Ashima Makol⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Ophthalmology, Mayo Clinic, Rochester, MN, ⁵Department of Ophthalmology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…
Abstract Number: 2265 • 2016 ACR/ARHP Annual Meeting
NET-Inducing Capacity Is a Biomarker in ANCA-Associated Vasculitis Independent of ANCA Antibodies
Tineke Kraaij¹, Sylvia Kamerling¹, Jaap Bakker², Francesca Brunini³, Charles Pusey³, Hans Ulrich Scherer⁴, René E.M. Toes⁵, Ton Rabelink¹, Cees van Kooten¹ and Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Chemistry, Leiden University Medical Center, Leiden, Netherlands, ³Imperial College, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Neutrophil extracellular traps (NETs) play an important role in the pathogenesis of ANCA-associated vasculitis (AAV). Sera of MPO-ANCA or PR3-ANCA positive patients can induce…
Abstract Number: 1938 • 2016 ACR/ARHP Annual Meeting
Bronchiectasis Are Highly Prevalent in Anti-MPO ANCA-Associated Vasculitis and Associate with a Distinct Disease Phenotype
Antoine Néel¹, Alexandra Espitia¹, Pierre Paul Arrigoni², Christelle Volteau³, Agathe Masseau¹, Marie Rimbert⁴, Christian Agard¹, Fadi Fakhouri⁵, Renan Liberge² and Mohamed Hamidou⁶, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Radiology Department, Nantes University Hospital, Nantes, France, ³Clinical Research Department, Nantes University Hospital, Nantes, France, ⁴Immunology Laboratory, Nantes University Hospital, Nantes, France, ⁵Nephrology Department, Nantes University Hospital, Nantes, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France
Background/Purpose: To assess the prevalence of bronchiectasis in a western cohort of ANCA positive GPA or MPA and its correlations with disease phenotype and outcome.…
Abstract Number: 2396 • 2016 ACR/ARHP Annual Meeting
Initiation of Dialysis in Pediatric ANCA-Associated Vasculitis
Karen James¹, Rui Xiao^2,3, Peter A. Merkel^4,5 and Pamela F. Weiss⁶, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare systemic vasculitidies with significant morbidity and mortality. There have been no comparative effectiveness studies of AAV…
Abstract Number: 1939 • 2016 ACR/ARHP Annual Meeting
Immunologic, Clinical and Demographic Correlates in 51 Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies
Grant Hughes¹ and Meredith Barnes², ¹University of Washington, Seattle, WA, ²Medicine, University of Washington, Seattle, WA
Background/Purpose: Exposure to illicit cocaine and its frequent adulterant, levamisole, is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of…
Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster² and Kenneth J. Warrington³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…
Abstract Number: 126 • 2016 ACR/ARHP Annual Meeting
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort
Philip McCarthy¹, Jenna Hudy², Marie Melville², Danielle Robson¹, John McKinnon², Sandeep Soman² and Kathleen Maksimowicz-McKinnon³, ¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, ²Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African-American populations. The significance of and associations with ANCA in African-Americans,…
Abstract Number: 1940 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Inflammatory Heart Disease in Eosinophillic Granulomatosis with Polyangiitis (Churg Strauss) Patients
Eloi Garcia Vives¹, Len Harty² and David Jayne³, ¹Vall d'Hebrón Hospital, Barcelona, Spain, ²Vasculitis & Lupus, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To establish EGPA/Churg Strauss inflammatory heart disease prevalence and develop an algorithm for heart disease screening in EGPA patients. Methods: An audit of all…
Abstract Number: 3045 • 2016 ACR/ARHP Annual Meeting
Immunometabolism in ANCA-Associated Glomerulonephritis
Peter C. Grayson¹, Sean Eddy², Viji Nair², Hemang Parikh³, Maja Lindenmeyer⁴, Laura Mariani², Huateng Huang², Wenjun Ju³, Casey Greene⁵, Clemens Cohen⁴, Jeffrey Krischer³, Matthias Kretzler², Peter A. Merkel⁶ and Felix H. Eichinger², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Division of Nephrology, University of Michigan, Ann Arbor, MI, ³University of South Florida, Tampa, FL, ⁴University of Munich, Munich, Germany, ⁵Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Mounting an inflammatory response requires immune cells to undergo major changes in metabolism. Mediators such as cytokines can specifically alter the metabolism of different…
Abstract Number: 127 • 2016 ACR/ARHP Annual Meeting
Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: a High Risk Group for Poor Outcomes
Philip McCarthy¹, Danielle Robson¹, Jenna Hudy², Marie Melville², John McKinnon², Sandeep Soman² and Kathleen Maksimowicz-McKinnon³, ¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, ²Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Antineutrophil antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African American populations. Little is known about the characteristics and outcomes of…
Abstract Number: 1941 • 2016 ACR/ARHP Annual Meeting
Retrospective Survey of Concomitant Autoimmune Diseases and Autoantibodies in a Cohort of Patients with ANCA-Associated Vasculitis (AAV)
Marta Casal Moura^1,2, Sergio Prieto-González², Georgina Espígol-Frigolé², Giuseppe Murgia^2,3, Marco Alba², Jose Hernández-Rodríguez² and Maria C. Cid², ¹Department of Internal Medicine, São João Hospital Center, Porto, Portugal, ²Hospital Clínic. University of Barcelona. IDIBAPS, Vasculitis Research Unit. Department of Autoimmune Diseases, Spain, Barcelona, Spain, ³University Clinic for Visceral Surgery and Medicine Bauchzentrum Bern, Bern, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) - granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) have heterogenous clinic…
Abstract Number: 3046 • 2016 ACR/ARHP Annual Meeting
Inflammatory Pathways As Shared Molecular Targets Across ANCA-Associated Vasculitis and Nephrotic Syndrome
Sean Eddy¹, Viji Nair¹, Hemang Parikh², Maja Lindenmeyer³, Laura Mariani¹, Felix H. Eichinger¹, Huateng Huang¹, Wenjun Ju², Casey Greene⁴, Peter C. Grayson⁵, Clemens Cohen³, Jeffrey Krischer², Peter A. Merkel⁶ and Matthias Kretzler¹, ¹Division of Nephrology, University of Michigan, Ann Arbor, MI, ²University of South Florida, Tampa, FL, ³University of Munich, Munich, Germany, ⁴Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Clinical trials in rare diseases typically test therapeutic efficacy in one disease defined by a particular clinical phenotype. Improved understanding of the molecular mechanisms…
Abstract Number: 978 • 2016 ACR/ARHP Annual Meeting
A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis
Peter A. Merkel¹, John Niles², Richard Jimenez³, Robert F. Spiera⁴, Brad H. Rovin⁵, Andrew Bomback⁶, Christian Pagnoux⁷, Antonia Potarca⁸, Thomas J. Schall⁹ and Pirow Bekker⁹, ¹Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ²Massachusetts General Hospital, Boston, MA, ³Rheumatology, The Seattle Arthritis Clinic, University of Washington Medicine, Northwest Hospital and Medical Center, Seattle, WA, ⁴Hospital for Special Surgery, Cornell, New York, NY, ⁵Ohio State University Medical Center, Columbus, OH, ⁶Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁸ChemoCentryx, Inc., Mountain View, CA, ⁹ChemoCentryx, Mountain View, CA
Background/Purpose: Complement 5a (C5a) is involved in the pathogenesis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). CCX168 is an orally administered, small molecule selective inhibitor of…
Abstract Number: 1942 • 2016 ACR/ARHP Annual Meeting
Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center
Sebastian Sattui¹, Andrew Westfall² and Angelo L. Gaffo³, ¹Tinsley Harrison Internal Medicine Residency Program, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Birmingham VA Medical Center, Birmingham, AL
Title: Presentation and Clinical Features of ANCA-associated Vasculitis in US African Americans: Experience From a Single Center Background/Purpose: Little is known about the presentation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].